Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 15, 2024

Selective CDK7 Inhibition for Therapy-Resistant Estrogen Receptor–Positive Breast Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer
Clin. Cancer Res 2024 Feb 21;[EPub Ahead of Print], C Guarducci, A Nardone, D Russo, Z Nagy, C Heraud, A Grinshpun, Q Zhang, A Freelander, MJ Leventhal, A Feit, G Cohen Feit, A Feiglin, W Liu, F Hermida-Prado, N Kesten, W Ma, C De Angelis, A Morlando, M O'Donnell, S Naumenko, S Huang, QD Nguyen, Y Huang, L Malorni, JS Bergholz Villafane, JJ Zhao, E Fraenkel, E Lim, R Schiff, GI Shapiro, R Jeselsohn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading